Quantitative Systematic Strategies LLC Biocryst Pharmaceuticals Inc Transaction History

Quantitative Systematic Strategies LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 06, 2021	BUY	$7.37 - $13.61 $219,987 - $406,244	29,849 Added 118.46%	55,047 $560,000
Q4 2020 Feb 09, 2021	SELL	$3.37 - $8.61 $139,861 - $357,332	-41,502 Reduced 62.22%	25,198 $188,000
Q3 2020 Nov 09, 2020	SELL	$3.43 - $5.53 $29,329 - $47,287	-8,551 Reduced 11.36%	66,700 $229,000
Q2 2020 Aug 04, 2020	BUY	$1.9 - $5.61 $58,020 - $171,312	30,537 Added 68.29%	75,251 $359,000
Q1 2020 May 06, 2020	SELL	$1.6 - $4.11 $89,744 - $230,529	-56,090 Reduced 55.64%	44,714 $89,000
Q4 2019 Feb 11, 2020	BUY	$1.59 - $3.45 $91,596 - $198,747	57,608 Added 133.36%	100,804 $348,000
Q3 2019 Nov 07, 2019	SELL	$2.5 - $3.73 $985 - $1,469	-394 Reduced 0.9%	43,196 $124,000
Q2 2019 Jul 25, 2019	BUY	$2.91 - $9.15 $94,918 - $298,454	32,618 Added 297.28%	43,590 $165,000
Q1 2019 Apr 15, 2019	SELL	$7.38 - $9.72 $161,201 - $212,313	-21,843 Reduced 66.56%	10,972 $89,000
Q4 2018 Feb 12, 2019	BUY	$6.51 - $9.6 $3,958 - $5,836	608 Added 1.89%	32,815 $265,000
Q3 2018 Nov 14, 2018	BUY	$5.52 - $7.99 $177,782 - $257,333	32,207 New	32,207 $246,000

260

173M

397K

444K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.52B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Quantitative Systematic Strategies LLC, based on Form 13F filings with the SEC.

Stay updated on Quantitative Systematic Strategies LLC with notifications on news.